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Background:  Co-administration  of  an investigational  quadrivalent  meningococcal  serogroups  A,  C, W  and
Y tetanus  toxoid  conjugate  vaccine  (MenACWY-TT)  with  the  fourth  dose  of  diphtheria–tetanus–acellular
pertussis  vaccine  (DTaP)  at  age  15–18  months  was  investigated  in  3-dose  Haemophilus  inﬂuenzae  type
b-meningococcal  serogroups  C/Y  conjugate  vaccine  (HibMenCY-TT)-primed  toddlers.
Methods:  Infants  were  randomized  (5:1)  and  primed  at 2, 4 and  6 months  of age  with  HibMenCY-TT  and
DTaP-hepatitis  B-inactivated  poliovirus  (DTaP-HBV-IPV)  vaccine,  or Hib-TT  and  DTaP-HBV-IPV  (Control).
HibMenCY-TT+  DTaP-HBV-IPV  vaccinees  were  re-randomized  (2:2:1)  to receive  MenACWY-TT  at  12–15
months  and  DTaP  at  15–18  months  (MenACWY-TT  group);  MenACWY-TT  co-administered  with  DTaP  at
15–18  months  (Coad  group);  or HibMenCY-TT  at 12–15  months  and DTaP  at 15–18  months  (HibMenCY-
TT group).  Controls  received  DTaP  at  15–18  months.  Only  children  in  the  HibMenCY-TT  group  received
a  fourth  dose  of Hib  conjugate  vaccine  due  to Hib  conjugate  vaccine  shortage  at  the  time  of  the  study.
DTaP  immunogenicity  and  reactogenicity  were  assessed  one  month  post-vaccination.
Results: Pre-deﬁned  statistical  non-inferiority  criteria  between  Coad  and Control  groups  were  met  for
diphtheria,  tetanus  and  ﬁlamentous  haemagglutinin  but not  pertussis  toxoid  and  pertactin.  Follow-
ing  vaccination  ≥99%  of children  had  anti-diphtheria/anti-tetanus  concentrations  ≥1.0  IU/ml.  Pertussis
GMCs  were  lower  in all  investigational  groups  versus  Control.  In  post hoc  analyses,  pertussis  antibodyAbbreviations: 95% CI, 95 percent conﬁdence interval; ACIP, Advisory Committee on Immunization Practices; AE, adverse event; ATP, according-to-protocol; Coad, co-
dministration treatment group who received MenACWY-TT+ DTaP at the fourth dose visit (15/18 months of age); DTaP, combined diphtheria–tetanus–acellular pertussis
accine; DTaP-HBV-IPV, combined diphtheria–tetanus–acellular pertussis–hepatitis B-inactivated poliovirus vaccine; FHA, ﬁlamentous hemagglutinin; GMC, geometric
ean  antibody concentrations; Hib-MenCY-TT, Meningococcal serogroup C and Y conjugate vaccine combined with Haemophilus inﬂuenzae type b conjugate vaccine; Hib-TT,
aemophilus inﬂuenzae type b conjugate vaccine; IMD, invasive meningococcal disease; MenACWY-DT, quadrivalent serogroups A, C, W-135 and Y conjugate vaccine with
ll  serogroups conjugated to the diphtheria toxoid carrier protein; MenACWY-CRM197, quadrivalent serogroups A, C, W-135 and Y conjugate vaccine with all serogroups
onjugated to CRM-197 (mutant diphtheria toxoid); MenACWY-TT, quadrivalent serogroups A, C, W-135 and Y conjugate vaccine with all serogroups conjugated to the
etanus  toxoid carrier protein; SAE, serious adverse event; PRN, pertactin; PRP, polyribosylribitol phosphate; PT, pertussis toxin; TT, tetanus toxoid; US, United States.
 This  study (110870/110871) is registered at www.clinicaltrials.gov NCT00614614.
∗ Corresponding author. Tel.: +1 8437975600; fax: +1 843 572 4872.
E-mail address: mikeyleonardi@yahoo.com (M.  Leonardi).
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concentrations  were  above  those  in  infants  following  3-dose  DTaP  primary  vaccination  in  whom  efﬁcacy
against  pertussis  was  demonstrated  (Schmitt,  von  König,  et  al.,  1996;  Schmitt,  Schuind,  et al.,  1996). The
reactogenicity  proﬁle  of the  Coad  group  was  similar  to DTaP  administered  alone.
Conclusion:  Routine  booster  DTaP  was  immunogenic  with  an acceptable  safety  proﬁle  when co-
administered  with  MenACWY-TT  vaccine  in  HibMenCY-TT-primed  toddlers.  These  data  support  the
administration  of  a fourth  DTaP  dose  following  a  4-dose  HibMenCY-TT  vaccination  series,  or  co-
administered  with  MenACWY-TT  in  HibMenCY-TT-primed  children.
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bosylribitol phosphate (PRP) conjugated to TT, and 5 g each
of MenC polysaccharide and MenY polysaccharide conjugated to© 2014  The  Authors.  P
. Introduction
Invasive disease due to Neisseria meningitidis (IMD) causes high
ortality and long-term sequelae, and prevention of infection
emains a public health goal [1,2]. Six meningococcal serogroups
A, B, C, W,  X and Y) cause the majority of disease worldwide
nd their distribution varies geographically [3–5]. In the United
tates (US) serogroups B, C and Y are the most commonly identiﬁed
isease-causing serogroups [2]. During 2005–2011, approximately
00–1200 cases of meningococcal disease occurred annually in
he US [6]. For the past decade, declines have occurred among all
ge groups and for all serogroups [6]. However, the highest IMD
urden continues to be observed in infants aged <1 year (approx-
mately 5.38 cases per 100,000 population, 1998–2007, US data),
ith around one-half caused by serogroup B [2]. The meningo-
occal serogroup C and Y vaccine combined with Haemophilus
nﬂuenzae type b conjugate vaccine (HibMenCY-TT, MenHibrixTM,
laxoSmithKline Vaccines) targets three major causes of meningi-
is [7–14] and is approved in the US for use as a four-dose series
or infants. HibMenCY-TT is recommended by the Advisory Com-
ittee on Immunization Practices (ACIP) for use in infants and
hildren at increased risk for IMD  such as those with comple-
ent deﬁciencies or asplenia including sickle cell disease, and
ay  be used as an alternative for routine vaccination against
ib [15]. Other US-licensed meningococcal vaccines approved for
se in infants are the quadrivalent serogroups A, C, W and Y
eningococcal conjugate vaccine MenACWY-CRM197 (MenveoTM,
ovartis) approved as a four-dose series in infants, and MenactraTM
MenACWY-DT, Sanoﬁ Pasteur) approved as a two-dose sched-
le in children aged 9–23 months. For children aged <2 years,
oth MenACWY-CRM197 and MenACWY-DT are recommended for
se in those with complement deﬁciencies or exposure due to
ravel/residence in an endemic area and, in addition, MenACWY-
RM197 is recommended in those with asplenia including sickle cell
isease [16,17].
The quadrivalent MenACWY vaccine with all serogroups
onjugated to tetanus toxoid (MenACWY-TT, NimenrixTM, Glaxo-
mithKline Vaccines), is licensed as a single dose from 12 months
f age in Europe, Australia and Canada, but remains investigational
n the US. One dose of MenACWY-TT was immunogenic and well
olerated in toddlers, children, adolescents and adults [18–25].
This study investigated the immunogenicity and safety of
enACWY-TT when used as an alternative meningococcal vac-
ine to the fourth dose of HibMenCY-TT in the second year of life.
n addition, since it is important to assess safety and immuno-
enicity of routinely co-administered vaccines when new antigens
re being proposed for inclusion in the vaccination schedule, and
ecause a fourth dose of diphtheria–tetanus–acellular pertussis
DTaP) vaccine is recommended at 15–18 months of age in the US,
he co-administration of DTaP with MenACWY-TT was evaluated.
ere we report immunogenicity and reactogenicity data pertaining
o the fourth DTaP dose (administered alone or with MenACWY-TT)
iven at 15–18 months of age. Immunogenicity of the meningococ-
al vaccine antigens is presented elsewhere [26].hed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
2. Methods
2.1. Study design
The study design is summarized in Table 1. Healthy infants
were enrolled and randomized 5:1 to receive primary vaccinations
at 2, 4 and 6 months of age with HibMenCY-TT and combined
DTaP-hepatitis B-inactivated poliovirus vaccine (DTaP-HBV-IPV),
or Hib-TT + DTPa-HBV-IPV (Control group). At 12–15 months of
age, children vaccinated with HibMenCY-TT + DTPa-HBV-IPV were
re-randomized (2:2:1) to receive MenACWY-TT at 12–15 months
of age followed by DTaP at 15–18 months of age (MenACWY-
TT group); MenACWY-TT co-administered with DTaP at 15–18
months of age (Coad group); or HibMenCY-TT at 12–15 months
of age followed by DTaP at 15–18 months of age (HibMenCY-TT
group). Children primed with Hib-TT + DTPa-HBV-IPV were not re-
randomized and received DTaP at 15–18 months of age (Control
group). All subjects were permitted to receive routine vaccines
recommended by ACIP. Subjects in the Coad, MenACWT-TT and
Control groups did not receive Hib booster vaccination because of
an ongoing shortage of Hib conjugate vaccine in the US at the time of
study conduct. Hib booster vaccinations were deferred until such
time as Hib conjugate vaccine was once again available [27]. The
booster phase was  open in design due to the different vaccination
schedules in each group.
Enrolling subjects at the commencement of primary vaccina-
tion ensured a cohort of subjects who  received DTaP vaccine from
the same manufacturer throughout the vaccination schedule, to
comply with ACIP recommendations [28].
2.1.1. Study subjects and vaccines
Participants were healthy infants between 6 and 12 weeks of
age, born after at least 36 weeks of gestation. Exclusion criteria
included prior receipt of any blood product or any of the study
vaccines since birth, except the ﬁrst dose of monovalent hepati-
tis B vaccine, and licensed non-study vaccines which was  allowed
within 30 days of dose-1. PCV7 and rotavirus vaccines were per-
mitted throughout the primary phase of the study, and licensed
inﬂuenza vaccine was  permitted once the subject reached six
months of age. A history of disease due to N. meningitidis, Hib, diph-
theria, tetanus, pertussis, hepatitis B, or polio, or vaccination against
any of these diseases performed outside of the study resulted in
exclusion from both phases. Subjects included in the booster phase
were to have received all three primary vaccination doses, and were
not to have received non-study Hib vaccine until 30 days after study
vaccination at 12–15 months of age or the fourth dose of PCV within
30 days of the booster dose of Infanrix (given at 15–18 months of
age).
One 0.5 ml  dose of HibMenCY-TT contained 2.5 g of Hib polyri-TT (total TT content ∼18 g). One 0.5 ml dose of MenACWY-TT
contained 5 g of each meningococcal serogroup A, C, W and Y
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Table 1
Study design.
Group name Primary vaccination Second year of life vaccinationa
(Visits 1–3) 12–15 months
(Visit 4)
1  month post
vaccination (Visit 5)
15–18 months (Visit 6) 1 month post vaccination
(Visit 7)
2, 4, 6 months Vaccination Blood sampling Blood sampling Vaccination Blood sampling
MenACWY-TT HibMenCY-TT + DTaP-
HBV-IPV
MenACWY-TT Yes – DTaP
Yes
HibMenCY-TT HibMenCY-TT + DTaP-
HBV-IPV
HibMenCY-TT Yes – DTaP Yes
Coad  HibMenCY-TT + DTaP-
HBV-IPV
No vaccination – Yes MenACWY-
TT + DTaP
Yes
Control Hib-TT + DTPa-HBV-IPV No vaccination – – DTaP Yes
Shaded areas indicate vaccination and blood sampling time points discussed in the present report.
a All subjects were permitted to receive routine vaccines recommended by the Advisory Committee on Immunization Practices. For measles, mumps, rubella, varicella,
hepatitis A and Hib vaccines, vaccination was to occur ≥30 days before or after administration of study vaccines. A shortage of Hib conjugate vaccine in the US at the time of
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che  study led ACIP to recommend deferral of the booster dose of Hib for all toddler
he  highest risk of invasive Hib disease. In compliance with this recommendation, 
ll  other groups were to receive the fourth dose of Hib conjugate vaccine when the
olysaccharide conjugated to TT (total TT content ∼44 g). The
yophilized meningococcal vaccines were reconstituted with sterile
aline for injection. The ﬁrst three doses of HibMenCY-TT or Hib-TT
ere administered intramuscularly in the left thigh and the fourth
eningococcal vaccine into the left thigh or arm.
DTaP (InfanrixTM, GlaxoSmithKline Vaccines) contained ≥30 IU
iphtheria toxoid, ≥40 IU TT, 25 g pertussis toxin (PT), 25 g ﬁl-
mentous hemagglutinin (FHA) and 8 g pertactin (PRN). DTaP
as administered intramuscularly into the right thigh or arm
n the Coad group, and in the left thigh or arm in the other
roups. The composition of the licensed DTaP-HBV-IPV (PediarixTM,
laxoSmithKline Vaccines) and Hib-TT (ActHIBTM, Sanoﬁ Pasteur)
accines is described elsewhere [10]..1.2. Study objectives
The primary objectives were assessed hierarchically; that is, an
bjective could only be considered formally met  after all previous
able 2
esults of the inferential analysis comparing the Coad group with Controls (primary obje
Hierarchy Endpoint Criteria for meetin
1 Immunogenicity of MenACWY-TT
administered at 12–15 months of age with
respect to antibody responses (hSBA) for
serogroups ACWY [26]
LL of 2-sided 95% 
(MenACWY-TT – H
serogroups CY
LL of 2-sided 95% 
for serogroups AW
2 Immunogenicity of MenACWY-TT
co-administered with Infanrix at 15–18
months of age with respect to antibody
responses (hSBA) for ACWY [26]
LL of 2-sided 95% 
HibMenCY-TT) is ≥
LL of 2-sided 95% 
serogroups AW
3a Anti-diphtheria % ≥1.0 IU/mL LL of 2-sided 95% 
3b  Anti-tetanus % ≥1.0 IU/mL LL of 95% CI for dif
Control) is ≥−10%
4a  Anti-PT GMC  LL of 95% CI for rat
is ≥0.67
4b  Anti-FHA GMC  LL of 95% CI for rat
is ≥0.67
4c Anti-PRN GMC  LL of 95% CI for rat
is ≥0.67
5  Non-inferiority of MenACWY-TT vs
HibMenCY-TT when administered at 12–15
months of age with respect to hSBA GMTs for
serogroups CY [26]
LL of 95% CI for rat
(MenACWY/HibM
LL of 2-sided 95% 
(Coad/HibMenCY-
5% CI – 95 percent conﬁdence interval; LL – lower limit of the 95% CI; PT – pertussis toxin;
RN  – pertactin; hSBA serum bactericidal activity using human complement source.
Coad group– subjects vaccinated with HibMenCY-TT + DTaP-HBV-IPV at 2, 4, 6 months a
Control group– subjects vaccinated with Hib-TT + DTaP-HBV-IPV at 2, 4, 6 months and D
he  Control group.
Endpoints could not be concluded as met  even though the pre-speciﬁed criterion was  mlow Hib conjugate vaccine to be preferentially administered to infants, who are at
osters were not administered to anyone except those in the HibMenCY-TT group.
hortage was resolved.
objectives were met  (see Table 2 for objectives listing and hierar-
chy).
The results of the primary objectives relating to the meningo-
coccal vaccine antigens are presented in the companion paper
[26]. In the present manuscript, only the endpoints related to
the DTaP booster vaccine are described: To demonstrate the non-
inferiority of DTaP co-administered with MenACWY-TT versus
DTaP administration alone in terms of the percentage of subjects
with anti-diphtheria and anti-tetanus antibody concentrations
≥1.0 IU/ml and anti-pertussis geometric mean concentrations
(GMCs) one month after vaccination at 15–18 months of age.
2.1.3. Immunogenicity assessment
Anti-diphtheria and anti-tetanus antibody concentrations weremeasured by ELISA with an assay cut-off of 0.1 IU/ml [29,30]. A
concentration ≥ cut-off was  considered to be indicative of sero-
protection [31–33]. Anti-PT, anti-FHA and anti-PRN IgG antibody
concentrations were measured by ELISA (cut-off of 5 EL.U/ml,
ctives: according-to-protocol immunogenicity cohort).
g objective Value [95% CI] Criteria met?
CI for difference
ibMenCY-TT) is ≥−10% for
CI (MenACWY-TT) is ≥80%
Yes
CI for difference (Coad –
−10% for serogroups CY
CI (Coad group) is ≥80% for
Yes
CI is ≥80% −0.39 [−2.20; 2.18] Yes
ference (Coad minus 0.68 [−0.82; 3.78] Yes
io (Coad divided by Control) 0.74 [0.65; 0.86] No
io (Coad divided by Control) 0.84 [0.71; 0.98] Yesc
io (Coad divided by Control) 0.60 [0.49; 0.73] No
io
enCY-TT) is ≥0.5
CI for ratio
TT) is ≥0.5
Yesc
 GMC  – geometric mean antibody concentration; FHA – ﬁlamentous hemagglutinin;
nd MenACWY-TT + DTaP at 15–18 months;
TaP at 15–18 months. There were 253–254 subjects in the Coad group and 146 in
et.
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bove which subjects were considered to be seropositive) [34,35].
o established correlate of protection against pertussis is cur-
ently deﬁned [36]. However, efﬁcacy of InfanrixTM in preventing
orld Health Organization-deﬁned pertussis was demonstrated in
 household-contact study conducted in Germany [37,38].
For the evaluation of DTaP immunogenicity, blood samples were
ollected from all subjects one month after the 15–18 months of
ge vaccination. Blood samples were also collected from subjects
n the Coad group prior to the 15–18 month vaccination and from
he MenACWY-TT and HibMenCY-TT groups one month after vacci-
ation at 12–15 months of age but were not planned to be assessed
or antibodies to pertussis antigens (Table 1). However, serum from
 subset of subjects in the MenACWY-TT and HibMenCY-TT groups
ere tested in a post hoc analysis of PRN responses as detailed
urther below.
.1.4. Safety and reactogenicity assessment
Speciﬁc local (pain, redness and swelling) and general symp-
oms (drowsiness, fever, irritability/fussiness and loss of appetite)
ere recorded by parents on diary cards for 8 days (Days 0–7) after
accination at 15–18 months of age. All other adverse events (AEs)
ere recorded for 31 days after the vaccinations in the fourth dose
hase. The occurrence of serious AEs (SAEs) and of speciﬁc AEs indi-
ating new onset of chronic illness and conditions prompting visits
o the Emergency Room were reported from dose 1 until 6 months
fter the last vaccination. The occurrence of rashes was  recorded
uring the fourth dose phase.
Symptom intensity for solicited AEs was graded on a 3-point
cale where grade 1 was mild, grade 2 was moderate, and grade
 was severe. Grade 3 symptoms were deﬁned for redness and
welling as diameter >30 mm;  for pain, if the subject cried when the
ffected limb was moved or the limb was spontaneously painful;
ever (any route) >40.0 ◦C; irritability/fussiness and drowsiness that
revented normal activity, and loss of appetite as not eating at all.
ll solicited local symptoms reported were automatically consid-
red to be vaccine-related. The relationship between vaccination
nd all other symptoms was assessed by the investigator.
.2. Statistical analyses
.2.1. Immunogenicity objectives
The analysis of immunogenicity was conducted on the Accord-
ng to Protocol (ATP) immunogenicity cohort that included all
accinated subjects who complied with protocol-deﬁned proce-
ures and for whom immunogenicity results were available.
Non-inferiority of anti-diphtheria and anti-tetanus antibody
esponses was concluded if the lower limits of the standardized
symptotic 95% conﬁdence intervals (95% CIs) on the difference
Coad group minus Control group) in the percentage of subjects
ith anti-diphtheria and anti-tetanus antibody concentrations
1.0 IU/ml were −10% or higher. Non-inferiority of anti-PT, anti-
HA and anti-PRN antibody GMCs was concluded if the lower limits
f the 2-sided 95% CIs on the GMC  ratios (Coad group divided by
he Control group) were ≥0.67.
Potential differences between groups were highlighted in
xploratory analyses if the asymptotic standardized 95% CI for the
ifference between two groups in percentages of subjects reach-
ng speciﬁed cutoffs excluded 0, or if the 95% CI for the GMC  ratio
etween groups excluded 1.
Additional post hoc analyses investigated anti-PRN antibody
esponses at Visit 5 (Table 1) in a subset of subjects (N = 150 in
he HibMenCY-TT group and N = 50 in the MenACWY-TT group).
era were not collected at this time point in the Coad group or
he Control groups, and sera collected at Visit 6 in the Coad group
ere not tested for DTaP responses, and so booster responses
ould not be assessed. A pertussis booster response was deﬁned 33 (2015) 924–932 927
as post-vaccination antibody concentrations ≥20 EL.U/ml in ini-
tially seronegative children, a post-vaccination increase ≥4 times
the pre-vaccination antibody concentration in children with pre-
vaccination antibody concentrations ≥5.0 EL.U/ml and <20 EL.U/ml,
or a two-fold increase in the pre-vaccination antibody concen-
tration in children with pre-vaccination antibody concentrations
≥20 EL.U/ml.
Reverse cumulative curves were used to present post-
vaccination antibody concentrations in each investigational group
against concentrations in infants after three-dose primary vacci-
nation with DTaP, and in whom vaccine efﬁcacy against pertussis
disease was subsequently demonstrated [37,38]. In the absence of
deﬁned serological correlates of protection for pertussis, it is gener-
ally accepted that efﬁcacy can be estimated by comparing antibody
levels to those observed in a group who received the same vaccine
components, and in which efﬁcacy was  demonstrated [39].
2.2.2. Safety objectives
The analysis of safety was  performed on the total vaccinated
cohort that included all vaccinated subjects. The incidence and
intensity of symptoms were calculated with exact 95% CI for each
group.
Analyses were performed using SAS® software 9.1 (SAS Institute
Inc., Cary, NC, United States) and ProcStatXact 7.0.
3. Results
3.1. Study subjects
Of 1305 toddlers who  were enrolled and vaccinated at 12–15
months of age, 1303 were taken into account in the analyses as
two subjects were erroneously removed from the analysis popula-
tion due to lack of clarity in their vaccination status, 1266 received
the booster dose of DTaP vaccine at 15–18 months of age (booster
dose received outside of the study was  the main exclusion criteria),
1238 vaccinated subjects completed the booster vaccination phase
of the study and 1209 completed the extended safety follow-up
phase. See Supplementary Fig. 1 for a summary of the study ﬂow
and Supplementary Table 1 for reasons why subjects withdrew or
were eliminated from the ATP cohorts. The groups were compa-
rable in terms of demographic characteristics, except that there
were more males (n = 165) than females (n = 138) in the Coad group
and more females (n = 97) than males (n = 78) in the Control group
(Supplementary Table 2).
3.2. Immunogenicity
The pre-deﬁned statistical criteria of non-inferiority between
the Coad group and the Control group in antibody seroprotection
rates for diphtheria and tetanus were met  (Table 2). The pre-deﬁned
statistical criteria of non-inferiority for pertussis antibody GMCs
were met  for FHA, but were not met  for PT and PRN (Table 2).
Because around 27% of subjects were excluded from the ATP anal-
ysis, a secondary analysis of the Total vaccinated cohort was  done.
For the total vaccinated cohort the non-inferiority criteria were met
for PT but not for PRN (Supplementary Table 3).
After vaccination at 15–18 months of age at least 99.2% of sub-
jects had anti-diphtheria and anti-tetanus antibody concentrations
of ≥1.0 IU/ml (Table 3). All but one subject were seropositive (anti-
body concentrations ≥5 EL.U/ml) for antibodies against pertussis
vaccine antigens. Exploratory analyses did not detect any differ-
ences between the MenACWY-TT group, the HibMenCY-TT group
and the Coad group versus the Control group in the percentage
of subjects with concentrations ≥1.0 IU/ml against diphtheria or
tetanus, or in seropositivity rates for each pertussis antigen.
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Table 3
Antibody responses to DTaP antigens one month after vaccination at 15–18 months of age (according-to-protocol immunogenicity cohort).
Antigen Group N % [95% CI] GMC [95% CI]
Diphtheria MenACWY-TT 252 99.2 [97.2; 99.9] 7.214 [6.592; 7.895]
≥1.0  IU/ml HibMenCY-TT 132 100 [97.2;  100] 7.360 [6.508; 8.323]
Coad  254 99.6 [97.8; 100] 7.458 [6.820; 8.155]
Control 146 100 [97.5;  100] 8.259 [7.347; 9.285]
Tetanus MenACWY-TT 252 99.2 [97.2; 99.9] 7.400 [6.900; 7.936]
≥1.0  IU/ml HibMenCY-TT 132 100 [97.2;  100] 8.458 [7.762; 9.215]
Coad  253 100 [98.6;  100] 11.751 [10.818; 12.765]
Control 146 99.3 [96.2; 100] 5.500 [4.877; 6.204]
PT  ≥5 EL.U/ml MenACWY-TT 252 100 [98.5;  100] 73.3 [66.7; 80.5]
HibMenCY-TT 130 100 [97.2;  100] 86.9 [75.7; 99.8]
Coad  254 100 [98.6;  100] 67.7 [62.0; 73.9]
Control 146 100 [97.5;  100] 91.0 [81.7; 101.4]
FHA  ≥5 EL.U/ml MenACWY-TT 252 100 [98.5;  100] 321.6 [289.9; 356.7]
HibMenCY-TT 132 100 [97.2;  100] 371.7 [321.5; 429.7]
Coad 253 100 [98.6;  100] 353.2 [320.8; 388.9]
Control 146 100 [97.5;  100] 422.9 [369.0; 484.6]
PRN  ≥5 EL.U/ml MenACWY-TT 252 99.6 [97.8; 100] 203.8 [178.7; 232.5]
HibMenCY-TT 132 100 [97.2;  100] 220.2 [183.7; 264.0]
Coad 253 100 [98.6;  100] 189.2 [167.2; 214.1]
Control 146 100 [97.5;  100] 315.1 [274.2; 362.1]
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Exploratory analyses suggested higher post-vaccination anti-
etanus GMCs in all 3 investigational groups compared to the
ontrol group (Fig. 1). Post-vaccination antibody GMCs for all per-
ussis antigens were lower in all 3 investigational groups compared
o the Control group (Fig. 1). Exploratory analyses detected sta-
istical differences in the GMCs for all pertussis antigens in the
enACWY-TT and Coad groups and for PRN in the HibMenCY-
T group. Compared to the Control group, the lowest anti-PT and
nti-PRN GMCs were observed in the Coad group.
The post hoc analyses evaluated anti-PRN responses since
on-inferiority criteria were not met  for either the ATP or total
ig. 1. Ratio of GMCs between groups one month after vaccination with DTaP or DTaP an
reen  = Coad group, orange = MenACWY-TT group, red = HibMenCY-TT group, each compa
ntibody concentration. ATP – according to protocol. D – diphtheria. T – tetanus. PT –
tatistically signiﬁcant difference between groups (exploratory analysis). (For interpretat
ersion of this article.)on above the speciﬁed cut-off; 95% CI = 95% conﬁdence intervals; GMC  = geometric
N – pertactin.
vaccinated cohort analyses for this antigen. They showed that anti-
PRN GMCs (ATP immunogenicity cohort) increased after the fourth
dose by 17.0-fold in the MenACWY-TT group and 12.7-fold in
the HibMenCY-TT group. Post-vaccination, 100% (95% CI: [91.0%;
100%]) of subjects from the MenACWY-TT group and 97.3% (95%
CI: [92.2%; 99.4%]) from the HibMenCY-TT group had a booster
response to PRN. Booster responses were observed in all subjects
of the subset tested in the HibMenCY-TT and MenACWY-TT groups
who were initially seronegative prior to the DTaP dose.
In all of the investigational groups, anti-PT, anti-FHA and anti-
PRN antibody concentrations post-vaccination were above those
d MenACWY-TT at 15–18 months of age (ATP immunogenicity cohort). Footnote:
red to the Control group. 95% CI = 95% conﬁdence intervals. GMC  = geometric mean
 pertussis toxin. FHA – ﬁlamentous hemagglutinin. PRN – pertactin. *Indicates a
ion of the references to color in this ﬁgure legend, the reader is referred to the web
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Fig. 2. Reverse cumulative curves of anti-PT, anti-FHA and anti-PRN antibody concentrations one month after the last booster vaccination. Footnote: Green = Coad group,
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ertussis disease was  subsequently demonstrated [37,38] (blue). PT – pertussis to
nterpretation of the references to color in this ﬁgure legend, the reader is referred 
bserved in infants following a 3-dose DTaP primary vaccination
eries (Fig. 2) in whom efﬁcacy against pertussis of 88.7% (2-sided
5% CI: [76.6%; 94.6%]) was demonstrated [37,38].
.3. Safety
Incidences of local and general solicited symptoms were compa-
able across the study groups (Fig. 3). The most frequently reported
olicited local and general AEs in each groups were injection site
edness and irritability/fussiness (Fig. 3). Irritability/fussiness was
he most frequently reported symptom of grade 3 intensity, but
as reported by not more than 4.1% of subjects in any treatment
roup. Fever >40 ◦C was reported by no more than one subjects in
ach group after DTaP vaccination. Reactogenicity and safety data
ertaining to the meningococcal vaccine doses are reported in the
ompanion manuscript for this study [26].
The percentages of subjects reporting SAEs, new onset of chronic
isease, and AEs resulting in an ER visit from the onset of primary
accination until 6 months after the fourth dose, and rash from the
ourth dose until 6 months after the fourth dose, were in the same
ange across the three groups (Supplementary Table 4). Three SAEs
eported in two subjects were considered to be vaccine-related:
ne case of a ﬂoppy infant 47 days post-dose-4 (Coad group), which
esolved after two days; and one case of convulsion 65 days after thech compared to the pooled DTaP group from study in whom vaccine efﬁcacy against
A – ﬁlamentous hemagglutinin. PRN – pertactin. ATP–according to protocol. (For
 web  version of this article.)
ﬁrst primary vaccination dose (HibMenCY-TT group) that resolved
in an infant who  later died of a second SAE (sudden infant death syn-
drome) 89 days post-dose-1. There were three other deaths during
the study (all in the primary phase), none of which were considered
to be vaccine related.
4. Discussion
Co-administration of DTaP and MenACWY-TT was immuno-
genic for all antigens in both vaccines [26], and induced
seroprotective antibody concentrations against diphtheria and
tetanus. Although there is no accepted correlate of protection
against pertussis disease, the GMCs for all pertussis antigens for all
groups were at least 10 times higher than the seropositive thresh-
old (Table 3). The statistical criteria for non-inferiority between
the Coad group and the Control group were met  for diphtheria,
tetanus and FHA, but were not met  for PT or PRN. We  observed
lower antibody GMCs to pertussis vaccine in all three of the
HibMenCY-TT-primed groups compared to the Control group. In
another study the magnitude of the pertussis GMCs post-dose-
3 in subjects primed with HibMenCY-TT co-administered with
DTaP-HBV-IPV and 7-valent pneumococcal conjugate vaccine was
lower than in subjects who had not received HibMenCY-TT, but
met  pre-speciﬁed non-inferiority criteria [10]. It is known that
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Fig. 3. Local and general solicited symptoms within 8 days after vaccination with DTaP (DTaP injection site in the Coad group) at 15–18 months of age (total vaccinated
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38.0 ◦C. Grade 3: Redness and swelling >30 mm.  Pain – cried when limb is touche
revented normal activity. Loss of appetite – not eating at all.
ib-TT in combination with DTaP antigens in the same syringe
esults in interference of the Hib response [40]. But this does not
ccount for our observation that pertussis responses were lower
n our study where the Hib and pertussis antigens were admin-
stered in separate limbs throughout the schedule, or why  lower
esponses were also seen after sequential administration of Hib
nd pertussis antigens. It should be noted that the control groups
n the study by Marshall et al. [10], and the present study are
ot comparable because a fourth dose of monovalent Hib vaccine
as not able to be administered to subjects participating in our
tudy. This meant that the Control group was the only group not
o receive a TT-conjugate vaccine during the fourth dose phase.
y contrast, post-vaccination anti-pertussis antibody GMCs were
bserved to be similar when a single dose of MenACWY-TT was
ither co-administered, or administered sequentially one month
part with DTaP-HBV-IPV/Haemophilus inﬂuenza type b vaccine
InfanrixTM hexa, GlaxoSmithKline Vaccines), to meningococcal
accine-naïve toddlers [23]. Anti-PRN antibody levels (and some-
imes other pertussis antigens) were reduced in studies conducted
n adolescent populations with MenACWY-DT and MenACWY-
RM197 when these vaccines were co-administered with adult
cellular pertussis vaccine formulations (www.clinicaltrials.gov
CT00777257) [41,42]. We  cannot exclude immune interference
etween the administered antigens, impacting on the pertussis
esponses. While there are differences between the responses
bserved here and previously published studies [7,23], it is worth
oting that the previously published data assessed the pertussis
esponses following the ﬁrst three doses, whereas the current pub-
ication evaluated the response to the fourth dose. It is possible
hat there is an impact of immune interference of the ﬁrst three
oses of HibMenCY-TT on the development of immune memory
o a fourth dose of pertussis vaccine. We  conducted additional
nalyses to assess the anti-PRN GMCs in two groups with pre-
TaP vaccination sera available. Increases in anti-PRN GMCs of at
east 12.7-fold and booster response rates of at least 97.3% were
bserved in the MenACWY-TT and HibMenCY-TT groups after the
TaP dose, indicating effective priming when DTPa-HBV-IPV was
o-administered with HibMenCY-TT in infancy, as well as immuno-
enicity of the DTaP booster. Furthermore, based on observation of
he reverse cumulative curves, anti-PT, FHA and PRN antibody con-
entrations in each investigational group seemed to be higher than
hose observed in a subset of subjects who were tested for immunes with at least one local symptom at the DTaP injection site. Any fever (any route)
taneously painful. Fever (any route) >40 ◦C. Irritability/fussiness and drowsiness –
responses following a third dose of DTaP, and who participated in a
German household contact efﬁcacy study, in which efﬁcacy after a
3-dose InfanrixTM immunization series against WHO-deﬁned per-
tussis was demonstrated to be 88.7% (2-sided 95% CI 76.6%; 94.6%)
[37,38]. These data suggest that the fourth DTaP dose can be admin-
istered to HibMenCY-TT-primed children, either alone after the
fourth HibMenCY-TT dose, or together with MenACWY-TT, while
maintaining a clinically acceptable immune response to all DTaP
antigens.
The safety and reactogenicity proﬁle of the study vaccines were
comparable. The reactogenicity proﬁle of MenACWY-TT and DTaP
co-administered was similar to that of DTaP alone, despite the addi-
tional TT administered to the Coad group.
Limitations of this study are discussed in Leonardi et al. [26]
and include that the study was powered only for non-inferiority
end points; all other comparisons were exploratory and should
be interpreted with caution considering that there was  no adjust-
ment for multiplicity. Due to the different vaccination schedules,
the study was  open-label beginning with the re-randomization at
12–15 months of age, which may  have inﬂuenced AE reporting
and attribution of the relationship of AEs to vaccination, but would
more likely be biased against the investigational product. Bias in
terms of immunogenicity is unlikely, as laboratory personnel were
blinded to treatment group during the laboratory analysis. We  were
unable to use a quadrivalent meningococcal conjugate vaccine as
control because the study was conducted prior to the availability
of a meningococcal conjugate vaccine licensed in the US for use in
children <2 years of age. A Hib vaccine shortage in the US  during
the study meant that the MenACWY-TT, Co-ad, and Control groups
did not receive the current US standard of care for Hib vaccina-
tion. Finally, blood samples were either not obtained or assessed
for antibodies to pertussis before and after each fourth dose phase
vaccination, which limited our ability to evaluate booster responses
in all of the treatment groups.
In subjects who completed the four-dose regimen of HibMenCY-
TT co-administered with the three-dose priming regimen of
DTPa-HBV-IPV, a fourth dose of DTaP generated antibody responses
to PT and FHA that were similar to those of a control group
primed with licensed Hib and DTPa-HBV-IPV vaccines followed
by DTaP. Furthermore, antibody responses to PT, FHA and PRN
that were comparable to those observed in infants in whom
efﬁcacy against pertussis was demonstrated [37,38]. Despite the
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ailure to demonstrate non-inferiority with respect to GMCs to PT
nd PRN, the results of the post hoc analysis suggest that DTaP
nd MenACWY-TT can be co-administered. Co-administration of
enACWY-TT and DTaP had a safety proﬁle that was  compara-
le to the licensed control vaccination regimen. These data provide
upport for the administration of a fourth dose of DTaP following
 four-dose HibMenCY-TT vaccination series, or co-administered
ith MenACWY-TT in HibMenCY-TT-primed children.
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